Descriptor: "Progeria" / Publication Type: Reports - Searchworks@Jio Institute Digital Library Search Results

Searchworks

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources

Your search keyword '"Progeria"' showing total 12 results

Start Over Descriptor "Progeria" Publication Type Reports

12 results on '"Progeria"'

1. Knowing and Treating Kosaki/Penttinen Syndromes (IKKoPeS)

Published: 2023

2. Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria

Author: Schering-Plough, Merck Sharp & Dohme LLC, Eiger BioPharmaceuticals, and Monica E. Kleinman, Principal Investigator
Published: 2023

3. Phase I/II Trial of Everolimus in Combination With Lonafarnib in Progeria

Author: Monica E. Kleinman, Medical Director, Transport & MSICU
Published: 2023

4. Phase I Study of Progerinin in Healthy Volunteers

Author: Amarex Clinical Research
Published: 2021

5. Lonafarnib for Patients With Hutchinson-Gilford Progeria Syndrome or Progeroid Laminopathy

Published: 2021

6. Umbilical Cord Blood Transfusion in Progeria Syndrome

Author: MinYoung Kim, MD, PhD, Head of Rehabilitation Medicine Department, Professor, Principal Investigator
Published: 2020

7. Clinical Studies of Progeria

Published: 2019

8. A Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria

Author: Dana-Farber Cancer Institute, Brigham and Women's Hospital, Schering-Plough, and Monica E. Kleinman, Critical Care
Published: 2019

9. Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for Progeria

Author: Schering-Plough and Monica E. Kleinman, Critical Care
Published: 2019

10. Zydus Lifesciences' arm acquires worldwide proprietary rights to Zokinvy.

Subjects: PROGERIA, INDUSTRIAL property
Abstract: Zokinvy is approved in the U.S. (2020), European Union and Great Britain (2022), and Japan (2024) for the treatment of Progeria [ABSTRACT FROM AUTHOR]
Published: 2024

11. Zydus Lifesciences informs about press release.

Subjects: PRESS releases, PROGERIA
Abstract: Zydus Lifesciences has informed that it enclosed a copy of press release dated May 4, 2024 titled 'Sentynl Therapeutics announces global acquisition of Zokinvy® (Lonafarnib) for treatment of Hutchinson-Gilford Progeria Syndrome from Eiger Biopharmaceuticals'.The above information is a part of company's filings submitted to BSE. [Extracted from the article]
Published: 2024

12. Treatment of the Hutchinson-Gilford Progeria Syndrome With a Combination of Pravastatin and Zoledronic Acid

Published: 2013

Catalog

Books, media, physical & digital resources

See catalog results